

MOXIFLOXACIN IN RESPIRATORY TRACT INFECTIONS

M. Miravittles

Moxifloxacin is a new broad spectrum 8-methoxyquinolon with high activity against both Gram(+) and Gram(-) microorganisms as well as against anaerobes and intracellular pathogens. It is also active against microorganisms that are resistant to other classes of antimicrobials, including penicillin- and macrolid-resistant pneumococci and β -lactamaseproducing *H. influenzae*.

An excellent activity against the above mentioned pathogens and good pharmacokinetic profile allows to use moxifloxacin for monotherapy of respiratory tract infections. High clinical efficacy and safety of moxifloxacin has been demonstrated in treatment in the controlled clinical trials.

The literature review of clinical trials moxifloxacin therapy in patients with community-acquired pneumonia and acute exacerbation chronic bronchitis is presented in the article.

Key words: moxifloxacin, fluoroquinolones, community-acquired pneumonia, acute exacerbation chronic bronchitis.